SAM
Sectoral Asset Management Portfolio holdings
AUM
$151M
This Quarter Return
+4.36%
1 Year Return
+14.02%
3 Year Return
+79.35%
5 Year Return
+153.48%
10 Year Return
+511.68%
AUM
$912M
AUM Growth
+$912M
(+14%)
Cap. Flow
+$98.3M
Cap. Flow
% of AUM
10.78%
Top 10 Holdings %
Top 10 Hldgs %
35.88%
Holding
80
New
13
Increased
28
Reduced
21
Closed
12
Top Buys
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$16.8M |
| 2 |
Gilead Sciences
GILD
|
$15.5M |
| 3 |
Exact Sciences
EXAS
|
$15.4M |
| 4 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
$12.5M |
| 5 |
Cogent Biosciences
COGT
|
$12M |
Top Sells
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$19.1M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$14.8M |
| 3 |
LOXO
Loxo Oncology, Inc
LOXO
|
$12.8M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$12.3M |
| 5 |
AbbVie
ABBV
|
$8.25M |
Sector Composition
| 1 | Healthcare | 91.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amicus Therapeutics
FOLD
$2.34B
| $51.2M | 5.62% | 3,405,541 +554,772 | +19% | +$8.34M |
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $36.4M | 3.99% | 1,647,692 -104,963 | -6% | -$2.32M |
|
|
LJPC
3
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $33.6M | 3.68% | 1,128,219 +273,918 | +32% | +$8.16M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.2B
| $32.3M | 3.54% | 397,903 +139,400 | +54% | +$11.3M |
|
5
Collegium Pharmaceutical
COLL
$1.22B
| $31.6M | 3.46% | 1,236,534 -190,328 | -13% | -$4.86M |
|
|
AERI
6
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $29.2M | 3.2% | 538,618 +169,821 | +46% | +$9.21M |
|
7
Novartis
NVS
$245B
| $28.7M | 3.15% | 355,296 -20,200 | -5% | -$1.63M |
|
8
Pfizer
PFE
$141B
| $28.5M | 3.13% | 804,274 -65,800 | -8% | -$2.34M |
|
9
Johnson & Johnson
JNJ
$427B
| $28.3M | 3.1% | 220,948 +6,599 | +3% | +$846K |
|
|
CELG
10
DELISTED
Celgene Corp
CELG
| $27.3M | 2.99% | 306,130 +74,300 | +32% | +$6.63M |
|
11
Teladoc Health
TDOC
$1.37B
| $26.1M | 2.86% | 646,828 -34,800 | -5% | -$1.4M |
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $24.3M | 2.66% | 327,698 +88,699 | +37% | +$6.57M |
|
|
13
Exact Sciences
EXAS
$8.98B
| $23.2M | 2.54% | 574,049 +381,599 | +198% | +$15.4M |
|
|
KTWO
14
DELISTED
K2M Group Holdings, Inc
KTWO
| $23.1M | 2.54% | 1,221,160 +56,748 | +5% | +$1.08M |
|
|
ABMD
15
DELISTED
Abiomed Inc
ABMD
| $22.4M | 2.45% | 76,817 -7,957 | -9% | -$2.32M |
|
16
UnitedHealth
UNH
$281B
| $19.7M | 2.16% | 92,203 +9,299 | +11% | +$1.99M |
|
17
Edwards Lifesciences
EW
$47.8B
| $18.1M | 1.99% | 129,959 -28,141 | -18% | -$3.93M |
|
18
Medtronic
MDT
$119B
| $18M | 1.98% | 224,600 +42,990 | +24% | +$3.45M |
|
19
Abbott
ABT
$231B
| $17.6M | 1.93% | 294,299 -88,610 | -23% | -$5.31M |
|
20
Acadia Pharmaceuticals
ACAD
$4.38B
| $17.6M | 1.93% | 783,424 -348,298 | -31% | -$7.83M |
|
|
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
| $16.9M | 1.86% | 320,799 +138,199 | +76% | +$7.3M |
|
|
ARRY
22
DELISTED
Array Biopharma Inc
ARRY
| $16.8M | 1.85% | +1,031,650 | New | +$16.8M |
|
|
PTLA
23
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $16.3M | 1.78% | 498,412 -38,002 | -7% | -$1.24M |
|
|
24
Gilead Sciences
GILD
$140B
| $15.5M | 1.69% | +205,000 | New | +$15.5M |
|
25
Eli Lilly
LLY
$657B
| $14.1M | 1.54% | 182,100 +17,900 | +11% | +$1.38M |
|